Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays?

El-Khoury JM, Bicer F, Bunch DR, Yuan C, Wang S.

Clin Chim Acta. 2013 Jan 16;415:230-2. doi: 10.1016/j.cca.2012.10.050. Epub 2012 Nov 7. No abstract available.

PMID:
23142648
2.

Minimal interference from paricalcitol (Zemplar®) in underivatized 1,25-dihydroxyvitamin D LC-MS/MS assays.

Pauwels S, Rozenski J, Jans I, Billen J, Vanderschueren D, Vermeersch P.

Clin Chim Acta. 2014 Feb 15;429:104-5. doi: 10.1016/j.cca.2013.12.002. Epub 2013 Dec 8. No abstract available.

PMID:
24326126
3.
4.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
5.

Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.

Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M.

J Nephrol. 2007 Jan-Feb;20(1):3-9. Review.

PMID:
17347966
6.

Technical and clinical evaluation of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay--comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method.

Cavalier E, Rousselle O, Ferrante N, Carlisi A, Le Goff C, Souberbielle JC.

Clin Chem Lab Med. 2013 Oct;51(10):1983-9. doi: 10.1515/cclm-2013-0138.

PMID:
23732682
7.

Determination of 1,25-dihydroxyvitamin D2 in rat serum using liquid chromatography with tandem mass spectrometry.

Sudsakorn S, Phatarphekar A, O'Shea T, Liu H.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 15;879(2):139-45. doi: 10.1016/j.jchromb.2010.11.025. Epub 2010 Dec 1.

PMID:
21168373
8.

Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.

Noertersheuser PA, Pradhan RS, Klein CE, Williams LA, Palaparthy R, Garimella TS, Lichtenberger O, Awni WM.

J Clin Pharmacol. 2012 Aug;52(8):1162-73. doi: 10.1177/0091270011412966. Epub 2011 Sep 22.

PMID:
21940716
9.

Spotlight on paricalcitol in secondary hyperparathyroidism.

Robinson DM, Scott LJ.

Treat Endocrinol. 2005;4(3):185-6. Review.

PMID:
15898824
10.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
11.

Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.

Bellasi A, Galassi A, Salvi P, Cozzolino M.

Blood Purif. 2013;36(1):12-6. doi: 10.1159/000350579. Epub 2013 May 25. Review.

PMID:
23736115
12.

A randomised clinical study of alfacalcidol and paricalcitol.

Hansen D.

Dan Med J. 2012 Feb;59(2):B4400.

PMID:
22293059
13.

Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.

Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB.

Nat Clin Pract Nephrol. 2007 Apr;3(4):227-32.

PMID:
17389892
14.

Standardization of vitamin D assays: art or science?

Fraser WD.

Ann Clin Biochem. 2009 Jan;46(Pt 1):3-4. doi: 10.1258/acb.2008.008225. No abstract available.

PMID:
19103954
15.

Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.

Al-Baaj F, Yadav P, Al-Rifai A.

J Ren Care. 2011 Jun;37(2):75-9. doi: 10.1111/j.1755-6686.2011.00230.x.

PMID:
21561542
16.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
17.

Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation.

Grant WB.

Age Ageing. 2006 Nov;35(6):645; author reply 645. Epub 2006 Sep 18. No abstract available.

PMID:
16982666
18.

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.

Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G.

Pediatr Nephrol. 2006 Oct;21(10):1434-9. Epub 2006 Aug 10.

PMID:
16900383
19.

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.

Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L.

Nephrol Dial Transplant. 2012 Jun;27(6):2263-9. doi: 10.1093/ndt/gfr668. Epub 2011 Dec 1.

PMID:
22140123
20.

Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years.

Pietras SM, Obayan BK, Cai MH, Holick MF.

Arch Intern Med. 2009 Oct 26;169(19):1806-8. doi: 10.1001/archinternmed.2009.361. No abstract available.

PMID:
19858440

Supplemental Content

Support Center